Mega CapHealthcareDividend

LLY — Eli Lilly and Company

Pharmaceuticals · Founded 1876 · Indianapolis, Indiana · CEO: David Ricks

Eli Lilly is a global pharmaceutical company at the center of the GLP-1 / obesity drug revolution. Mounjaro (tirzepatide) for diabetes and Zepbound for weight loss have made Lilly one of the fastest-growing and most valuable pharmaceutical companies in the world.

How Eli Lilly and Company Makes Money

Mounjaro / Zepbound (tirzepatide) for diabetes and obesity — the primary growth driver

Verzenio (breast cancer), Jardiance (diabetes), and Taltz (autoimmune)

Neuroscience pipeline including donanemab for Alzheimer's disease

Animal health spin-off completed (Elanco), allowing pure pharma focus

Key Metrics Investors Watch

Mounjaro / Zepbound revenue growth and supply scaling
GLP-1 market share vs. Novo Nordisk (Ozempic, Wegovy)
Pipeline clinical trial data (Alzheimer's, oncology, immunology)
Manufacturing capacity expansion for tirzepatide
Revenue growth rate and EPS trajectory

Competitive Advantages

Tirzepatide (Mounjaro/Zepbound) shows best-in-class efficacy in both diabetes and obesity
GLP-1/obesity is a potential $100B+ market — Lilly and Novo Nordisk are the clear leaders
Strong innovation pipeline across multiple therapeutic areas including Alzheimer's
Manufacturing investments to scale production and address chronic supply constraints

Key Risks

Premium valuation already prices in enormous future growth expectations
Competition from Novo Nordisk (Wegovy/Ozempic) and next-generation GLP-1 competitors
Manufacturing capacity constraints have limited supply and sales growth
Insurance coverage and out-of-pocket costs could limit patient access to GLP-1 drugs

Dividend & Capital Return

Lilly pays a quarterly dividend and has a long history of increases. The yield is modest relative to the stock price due to Lilly's significant price appreciation.

I Document Every Trade — Even the Losses

Options record: 1W-8L. Net worth: 100% GSE preferred. Get the unfiltered updates.

Unsubscribe anytime. I respect your inbox more than Congress respects property rights.

Frequently Asked Questions

Is Eli Lilly stock overvalued?

Lilly trades at a premium valuation reflecting the enormous market potential of its GLP-1 obesity franchise. Whether it's overvalued depends on how large the obesity drug market becomes and Lilly's competitive position. This is educational content, not financial advice.

What is Mounjaro / Zepbound?

Mounjaro (for diabetes) and Zepbound (for obesity) are brand names for tirzepatide, Eli Lilly's GLP-1 receptor agonist. These drugs have shown best-in-class weight loss and blood sugar control results.

How big is the obesity drug market?

Analysts project the GLP-1 / obesity drug market could reach $100B+ annually within a decade. Eli Lilly and Novo Nordisk are the two dominant players.

Does Eli Lilly pay a dividend?

Yes, Lilly pays a quarterly dividend that has been increased for many consecutive years. The yield appears low due to the stock's strong price appreciation.

Is Lilly competing with Novo Nordisk?

Yes, Eli Lilly (Mounjaro/Zepbound) and Novo Nordisk (Ozempic/Wegovy) are the two leaders in the GLP-1 obesity market. Clinical data suggests tirzepatide has a modest efficacy advantage.

Related Stocks

JNJ

Johnson & Johnson

Healthcare

Johnson & Johnson is a global healthcare company operating in pharmaceuticals (Innovative Medicine) and medical devices (MedTech). Following the spin-off of its consumer health division as Kenvue in 2023, JNJ is now focused on higher-growth, higher-margin healthcare segments.

ABBV

AbbVie Inc.

Healthcare

AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and eye care. Spun off from Abbott Laboratories in 2013, AbbVie is best known for Humira (the world's best-selling drug of all time) and its successor drugs Skyrizi and Rinvoq.

MRK

Merck & Co., Inc.

Healthcare

Merck is a global pharmaceutical and animal health company known for Keytruda, the world's best-selling cancer immunotherapy drug. The company has a strong pipeline in oncology, vaccines, and cardiometabolic diseases and operates one of the largest animal health businesses globally.

Recommended Resources

Tools & books I actually use and recommend

SeekingAlpha Premium

Quant ratings, earnings transcripts, and the stock analysis community where I published 300+ articles.

Try SeekingAlpha

The Intelligent Investor

Ben Graham's timeless guide to value investing. The book Warren Buffett calls "the best investing book ever written."

View on Amazon

Interactive Brokers

Low commissions, global market access, and professional-grade tools. This is where I hold my positions.

Open an Account

Some links above are affiliate links. I only recommend products I personally use. See my full disclosures.

Keep Exploring

Hub

All Stocks

Browse all 134 stock profiles by sector.

Best Stocks For Beginners

Curated stock picks for new investors by goal.

Financial Glossary

Understand the terms investors use every day.

Stock vs ETF

Individual stocks vs ETFs — which is right for you?

ETF Profiles

Deep dives on 90+ ETFs across every category.

Buying Your First Stock

How to open a brokerage and buy your first share.

Browse All 134 Stock Profiles

Company information is based on publicly available disclosures and widely-known business facts. No specific price, earnings, or real-time market data is included. This is educational content — not investment advice.